CompletedPhase 3NCT02059135

Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia

Studying Preeclampsia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
rEVO Biologics
Principal Investigator
Michael Paidas, MD
Yale New Haven Hospital
Intervention
Recombinant human antithrombin (ATryn)(biological)
Enrollment
120 target
Eligibility
16 years · FEMALE
Timeline
20142016

Study locations (23)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02059135 on ClinicalTrials.gov

Other trials for Preeclampsia

Additional recruiting or active studies for the same condition.

See all trials for Preeclampsia

← Back to all trials